Anthem Biosciences profit and loss

Latest FY26

Revenue: ₹2,124cr
EBITDA: ₹834cr
Net profit: ₹592cr
EPS: ₹10.55

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026

Expenses
	2,002	2,124
	158	156
	2,160	2,280
	700	714
	27.7	98.7
	290	283
	6.2	6.9
	138	134
	192	196
	1,353	1,431
	793	834
	655	700
Profit
	807	849
	−24.4	−24.4
	783	824
	226	241
	−19.3	−8.9
	207	232
	576	592
	576	592
	−2.2	−1.6
	574	590
Per share
	₹10.25	₹10.55
	₹10.15	₹10.43
Other comprehensive income — detail
	−2.2	−1.6
	−2.4	−1.6
	−0.0	0.0
Per share — as-filed variants
	₹10.25	₹10.55
	₹10.15	₹10.43
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,275	1,312
	63.7%	61.8%
Adjusted (ex-exceptional items) — derived
	807	849
	−24.4	−24.4
	594	609
	₹10.57	₹10.86

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ANTHEM₹830.15

Anthem Biosciences Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersSYNGENE DIVISLAB GLAXO AJANTPHARM IPCALAB ABBOTINDIA MEDANTA GLENMARKMcap ₹46,631 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	2,124.3	2,002.3
Other Income	155.8	157.9
Total Income	2,280.1	2,160.2
Expenses
+ Cost of Materials Consumed	713.6	700.0
+ Changes in Inventories	98.7	27.7
+ Employee Benefit Expense	282.7	289.5
+ Finance Costs	6.9	6.2
+ Depreciation & Amortisation	134.1	137.6
+ Other Expenses	195.5	192.3
Total Expenses	1,431.5	1,353.2
EBITDA	833.8	792.9
EBIT	699.7	655.3
Profit
PBT before Exceptional Items	848.6	807.0
+ Exceptional Items	-24.4	-24.4
Pretax Income	824.2	782.6
+ Current Tax	241.3	225.9
+ Deferred Tax	-8.9	-19.3
Tax Expense	232.4	206.6
Net Income	591.8	575.9
+ Net Income — Continuing Ops	591.8	575.9
+ Other Comprehensive Income	-1.6	-2.2
Total Comprehensive Income	590.2	573.8
Per Share
Basic EPS	10.55	10.25
Diluted EPS	10.43	10.15
Other Comprehensive Income — detail
+ Other Comprehensive Income	-1.6	-2.2
+ Items NOT to be Reclassified to P&L	-1.6	-2.4
+ Tax on Items NOT to be Reclassified	0.0	-0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	10.55	10.25
Diluted EPS — Continuing Operations	10.43	10.15
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,312.1	1,274.7
Gross Margin %	61.76	63.66
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	848.6	807.0
− Exceptional Items (reconciliation)	-24.4	-24.4
Net Income Adj (tax-effected)	609.3	593.9
EPS Adj	10.86	10.57
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00
Filed Debt Equity	0.02	1.18
Filed Dscr	143.55	28.54
Filed Iscr	120.56	163.93
Paid Up Equity Capital	112.3	112.7

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.